Although BTK inhibitors are associated with a heightened risk of infections of any grade, fungal infections are seldom reported in clinical trials. Ibrutinib, as the first agent in this class, remains the most extensively studied and provides ample data in terms of its side effect profile. Here, BTK is linked to fungal infectious disease.